Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | EVP, Global Manufacturing | June 07, 2018 | June 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date June 07, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,226 |
Reported balance
After 2018-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-07 · Sale · Disposed 183 · Balance 15,226 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: This number includes unvested restricted stock units previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: This number includes unvested restricted stock units previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2018 Filed Jun 8, 2018 20:45 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 183 | $92.73 | $16,969.59 |
DisclosureSEC source: 0001127602-18-020492 · form4.xml · nonDerivative · entry 1 Ryding Neil Mr. · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,226 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 25, 2017 Filed May 23, 2018 21:09 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 267 | $46.76 | $12,484.92 |
DisclosureSEC source: 0001127602-18-018570 · form4.xml · nonDerivative · entry 4 Ryding Neil Mr. · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,409 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 20, 2017 Filed May 23, 2018 21:09 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 346 | $45.70 | $15,812.20 |
DisclosureSEC source: 0001127602-18-018570 · form4.xml · nonDerivative · entry 3 Ryding Neil Mr. · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,676 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 21:50 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,836 | $41.64 Strike: $41.64 | $409,571.04 |
DisclosureSEC source: 0001127602-17-020967 · form4.xml · derivative · entry 2 Ryding Neil 122-62-507 · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,836 Underlying: Common Stock · 9,836 shares Expires 2024-06-06 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 21:50 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,401 | $41.64 | $99,977.64 |
DisclosureSEC source: 0001127602-17-020967 · form4.xml · nonDerivative · entry 1 Ryding Neil 122-62-507 · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,676 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| January 13, 2017 Filed May 23, 2018 21:09 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 3,303 | $40.32 | $133,176.96 |
DisclosureSEC source: 0001127602-18-018570 · form4.xml · nonDerivative · entry 2 Ryding Neil Mr. · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,022 F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantPerformance Shares · Derivative | 6,577 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-065407 · form4.xml · derivative · entry 3 Ryding Neil 122-62-507 · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,577 Underlying: Common Stock · 6,577 shares Expires 2019-12-31 F3 · derivative.exercise_date: Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d). Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,187 | $34.21 Strike: $34.21 | $485,337.27 |
DisclosureSEC source: 0001127602-16-065407 · form4.xml · derivative · entry 2 Ryding Neil 122-62-507 · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,187 Underlying: Common Stock · 14,187 shares Expires 2023-10-25 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 23:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 3,288 | $34.21 | $112,482.48 |
DisclosureSEC source: 0001127602-16-065407 · form4.xml · nonDerivative · entry 1 Ryding Neil 122-62-507 · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,275 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| October 20, 2016 Filed May 23, 2018 21:09 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 351 | $34.16 | $11,990.16 |
DisclosureSEC source: 0001127602-18-018570 · form4.xml · nonDerivative · entry 1 Ryding Neil Mr. · CIK 0001654614 · EVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,325 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.